Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
Search
Tag: lower-risk
– New findings demonstrate a 72% HI-E response rate at Week 16…